NASDAQ:BLRX

BioLineRx - BLRX Stock Forecast, Price & News

$0.72

+0.03 (+3.67%)

(As of 12/2/2022 03:50 PM ET)

Add

Compare

Today's Range: $0.69
▼
$0.72
50-Day Range: $0.60
▼
$0.95
52-Week Range: $0.57
▼
$3.02

Volume: 2,500 shs
Average Volume: 240,124 shs
Market Capitalization: $44.30 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $6.00

BioLineRx MarketRank™ Forecast

Analyst Rating: N/A
0.00 Rating Score
Upside/Downside: 738.6% Upside
$6.00 Price Target
Short Interest: Healthy
0.42% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.51) to ($0.53) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.30 out of 5 stars

Medical Sector

993rd out of 1,033 stocks

Pharmaceutical Preparations Industry

482nd out of 502 stocks

2.0

Analyst's Opinion

Price Target Upside/Downside
According to analysts' consensus price target of $6.00, BioLineRx has a forecasted upside of 738.6% from its current price of $0.72.
Amount of Analyst Coverage
BioLineRx has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.42% of the outstanding shares of BioLineRx have been sold short.
Short Interest Ratio / Days to Cover
BioLineRx has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in BioLineRx has recently increased by 7.30%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
BioLineRx does not currently pay a dividend.
Dividend Growth
BioLineRx does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BLRX.

1.5

News and Social Media Coverage

News Sentiment
BioLineRx has a news sentiment score of -0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.33 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for BioLineRx this week, compared to 1 article on an average week.
Search Interest
Only 1 people have searched for BLRX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
MarketBeat Follows
3 people have added BioLineRx to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, BioLineRx insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 1.10% of the stock of BioLineRx is held by insiders.
Percentage Held by Institutions
Only 2.22% of the stock of BioLineRx is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for BioLineRx are expected to decrease in the coming year, from ($0.51) to ($0.53) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of BioLineRx is -1.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of BioLineRx is -1.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
BioLineRx has a P/B Ratio of 0.50. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About BioLineRx (NASDAQ:BLRX) Stock

BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

Receive BLRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioLineRx and its competitors with MarketBeat's FREE daily newsletter.

BLRX Stock News Headlines

November 15, 2022 | finance.yahoo.com

BioLineRx Reports Third Quarter 2022 Financial Results and Recent Corporate and Portfolio Updates

November 10, 2022 | finance.yahoo.com

BioLineRx Announces U.S. FDA Acceptance of New Drug Application for APHEXDA® (motixafortide) in Stem Cell Mobilization

November 10, 2022 | finance.yahoo.com

BioLineRx to Report Third Quarter 2022 Results on November 15, 2022

November 4, 2022 | finance.yahoo.com

BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification

November 3, 2022 | finance.yahoo.com

BioLineRx Announces Presentations on Cost-Effectiveness of Motixafortide in Multiple Myeloma and Program for Potential Motixafortide Indication Expansion in Gene Therapy at the 64th American Society of Hematology (ASH) Annual Meeting

November 2, 2022 | finance.yahoo.com

BLRX: Cast Off the Bowlines: Aphexda Commercialization

September 28, 2022 | finance.yahoo.com

BioLineRx Announces U.S. Commercialization Plan for APHEXDA (Motixafortide) in Stem Cell Mobilization - Yahoo Finance

September 27, 2022 | finance.yahoo.com

BioLineRx Announces U.S. Commercialization Plan for APHEXDA (Motixafortide) in Stem Cell Mobilization

September 21, 2022 | streetinsider.com

Form 6-K BioLineRx Ltd. For: Sep 21 - StreetInsider.com

September 20, 2022 | businesswire.com

INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in BioLineRx Ltd. with Losses of $100000 to Contact the Firm - Business Wire

September 19, 2022 | finance.yahoo.com

BioLineRx Announces $15 Million Registered Direct Offering - Yahoo Finance

September 19, 2022 | businesswire.com

EQUITY ALERT: Rosen Law Firm Encourages BioLineRx Ltd. Investors to Inquire About Securities Class Action Investigation – BLRX - Business Wire

September 19, 2022 | seekingalpha.com

BioLineRx stock slips on $15M securities offering - Seeking Alpha

September 19, 2022 | finance.yahoo.com

BioLineRx Announces $15 Million Registered Direct Offering

September 15, 2022 | streetinsider.com

BioLineRx (BLRX) Enters $40M Non-Dilutive Debt Financing Agreement with Kreos Capital - StreetInsider.com

September 15, 2022 | finance.yahoo.com

BioLineRx Secures $40M In Debt Financing To Fund Commercialization Of Stem Cell Mobilization For Blood Cancer

September 15, 2022 | finance.yahoo.com

BioLineRx Announces $40 Million Non-Dilutive Debt Financing Agreement with Kreos Capital

September 14, 2022 | finance.yahoo.com

New Therapeutics Options in Pancreatic Ductal Adenocarcinoma Pipeline as 40+ Key Companies are Working on Drug Profiles | DelveInsight - Yahoo Finance

September 14, 2022 | finance.yahoo.com

BioLineRx Announces Submission of New Drug Application (NDA) to FDA for Motixafortide in Stem Cell Mobilization - Yahoo Finance

September 13, 2022 | benzinga.com

BioLine Rx (NASDAQ:BLRX) – BioLineRx Announces Submission of New Drug Application (NDA) to FDA for Motixa - Benzinga

September 12, 2022 | benzinga.com

BioLine Rx (NASDAQ:BLRX) – BioLineRx Announces Submission Of New Drug Application To FDA For Motixafortid - Benzinga

September 12, 2022 | nasdaq.com

BioLineRx Announces Submission Of Its First NDA - Quick Facts

September 12, 2022 | finance.yahoo.com

BioLineRx Announces Submission of New Drug Application (NDA) to FDA for Motixafortide in Stem Cell Mobilization

September 2, 2022 | finance.yahoo.com

Global Actinic Keratosis Treatment Market to Reach $10.08 Billion by 2027 at a CAGR of 10.61% - Yahoo Finance

August 23, 2022 | benzinga.com

BLRX: September NDA - Benzinga

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive BLRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioLineRx and its competitors with MarketBeat's FREE daily newsletter.

BLRX Company Calendar

Last Earnings: 12/08/2021
Today: 12/05/2022
Fiscal Year End: 12/31/2022
Next Earnings (Estimated): 3/15/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:BLRX
CUSIP: N/A
CIK: 1498403
Web: www.biolinerx.com
Phone: (728) 642-9100
Fax: 972-8642-9101
Employees: 38
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $6.00
High Stock Price Forecast: $6.00
Low Stock Price Forecast: $6.00
Forecasted Upside/Downside: +733.3%
Consensus Rating: N/A
Rating Score (0-4): 0.00
Research Coverage: 0 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.49)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-27,050,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -38.63%
Return on Assets: -30.78%

Debt

Debt-to-Equity Ratio: 0.15
Current Ratio: 7.12
Quick Ratio: 7.12

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.43 per share
Price / Book: 0.50

Miscellaneous

Outstanding Shares: 61,524,000
Free Float: 60,847,000
Market Cap: $44.30 million
Optionable: Not Optionable
Beta: 1.79

Key Executives

Mr. Philip A. Serlin CPA (Age 62)
M.B.A., CPA, MBA, Chief Exec. Officer
Comp: $644k

Ms. Mali Zeevi CPA (Age 46)
CPA, Chief Financial Officer
Comp: $391k

Dr. Ella Sorani (Age 54)
Chief Devel. Officer
Comp: $414k

Dr. Abi Vainstein-Haras M.D. (Age 47)
Chief Medical Officer
Comp: $391k

Advocate Norman Kotler (Age 70)
Internal Enforcement Officer, Gen. Counsel and Corp. Sec.

Ms. Liron Shemesh-Darvish M.B.A.
Ph.D., Sr. Director & Head of Preclinical Devel.

Ms. Jael Birenberg M.Sc.
Sr. Director & Head of RA, QA and PhV

Ms. Tsipi Keren-Lehrer B.Sc.
L.L.B., Head of BD & Strategic Advisor

Ms. Holly W. May M.B.A.
Pres of BioLineRx USA

Mr. Raziel Fried
Treasurer & Budgetary Control Director

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

BLRX Stock - Frequently Asked Questions

What is BioLineRx's stock price forecast for 2023?: 0 Wall Street analysts have issued 1 year price objectives for BioLineRx's stock. Their BLRX share price forecasts range from $6.00 to $6.00. On average, they anticipate the company's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 738.6% from the stock's current price.
View analysts price targets for BLRX or view top-rated stocks among Wall Street analysts.
How have BLRX shares performed in 2022?: BioLineRx's stock was trading at $2.04 at the beginning of the year. Since then, BLRX shares have decreased by 64.9% and is now trading at $0.7155.
View the best growth stocks for 2022 here.
Are investors shorting BioLineRx?: BioLineRx saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 260,200 shares, an increase of 7.3% from the October 31st total of 242,500 shares. Based on an average trading volume of 363,300 shares, the short-interest ratio is presently 0.7 days.
View BioLineRx's Short Interest.
When is BioLineRx's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 15th 2023.
View our BLRX earnings forecast.
How were BioLineRx's earnings last quarter?: BioLineRx Ltd. (NASDAQ:BLRX) issued its quarterly earnings results on Wednesday, December, 8th. The biotechnology company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.01.

What other stocks do shareholders of BioLineRx own?: Based on aggregate information from My MarketBeat watchlists, some companies that other BioLineRx investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Zosano Pharma (ZSAN), KushCo (KSHB), Aeterna Zentaris (AEZS), CNBX Pharmaceuticals (CNBX), Pennsylvania Real Estate Investment Trust (PEI), Savara (SVRA), Bionano Genomics (BNGO) and Gran Tierra Energy (GTE).
What is BioLineRx's stock symbol?: BioLineRx trades on the NASDAQ under the ticker symbol "BLRX."
Who are BioLineRx's major shareholders?: BioLineRx's stock is owned by many different institutional and retail investors. Top institutional investors include Altium Capital Management LP (6.74%), Armistice Capital LLC (4.55%), Renaissance Technologies LLC (0.11%), Apollon Wealth Management LLC (0.08%), PVG Asset Management Corp (0.10%) and Virtu Financial LLC (0.08%).
How do I buy shares of BioLineRx?: Shares of BLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is BioLineRx's stock price today?: One share of BLRX stock can currently be purchased for approximately $0.72.
How much money does BioLineRx make?: BioLineRx (NASDAQ:BLRX) has a market capitalization of $44.02 million. The biotechnology company earns $-27,050,000.00 in net income (profit) each year or ($0.49) on an earnings per share basis.
How can I contact BioLineRx?: BioLineRx's mailing address is 2 HAMA-AYAN STREET, MODI-IN L3, 7177871. The official website for the company is www.biolinerx.com. The biotechnology company can be reached via phone at (728) 642-9100, via email at ir@biolinerx.com, or via fax at 972-8642-9101.

This page (NASDAQ:BLRX) was last updated on 12/5/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial